Daniel Lynch - 11 Nov 2021 Form 4 Insider Report for 2seventy bio, Inc. (TSVT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
16 Nov 2021, 05:44:58 UTC
Prior SEC filing
21 Oct 2021
Next SEC filing
20 May 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Teresa Jurgensen, Attorney-in-Fact

Key filing fact

Daniel Lynch filed Form 4 for 2seventy bio, Inc. (TSVT) on 16 Nov 2021.

Key facts

  • This page summarizes Daniel Lynch's Form 4 filing for 2seventy bio, Inc. (TSVT).
  • 10 reported transactions and 9 derivative rows are listed below.
  • Accepted by SEC: 16 Nov 2021, 05:44.

Change

  • Previous filing in this sequence was filed on 21 Oct 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TSVT transaction

Common Stock

Award

Transaction value
$0
Shares
+2,803
Change %
+106%
Price
$0.000000
Shares after
5,453
Date
11 Nov 2021
Ownership
Direct
Footnotes
F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TSVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+7,660
Change %
Price
$0.000000
Shares after
7,660
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,660
Exercise price
$8.55
Footnotes
F5, F6
TSVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+3,445
Change %
Price
$0.000000
Shares after
3,445
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,445
Exercise price
$39.07
Footnotes
F5, F6
TSVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+3,445
Change %
Price
$0.000000
Shares after
3,445
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,445
Exercise price
$287.25
Footnotes
F5, F6
TSVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+1,837
Change %
Price
$0.000000
Shares after
1,837
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,837
Exercise price
$74.34
Footnotes
F5, F6
TSVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+1,837
Change %
Price
$0.000000
Shares after
1,837
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,837
Exercise price
$172.37
Footnotes
F5, F6
TSVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+1,837
Change %
Price
$0.000000
Shares after
1,837
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,837
Exercise price
$284.33
Footnotes
F5, F6
TSVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+1,837
Change %
Price
$0.000000
Shares after
1,837
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,837
Exercise price
$189.47
Footnotes
F5, F6
TSVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+1,378
Change %
Price
$0.000000
Shares after
1,378
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,378
Exercise price
$99.53
Footnotes
F5, F6
TSVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+4,507
Change %
Price
$0.000000
Shares after
4,507
Date
11 Nov 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,507
Exercise price
$50.98
Footnotes
F5, F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

In connection with the separation (the "Separation") of seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"), the reporting person received restricted stock units, each representing the right to receive a share of 2seventy's common stock, as a result of the adjustment of existing bluebird restricted stock units prior to the Separation (see footnotes 2 and 3). This restricted stock unit award vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders.

Footnote F2

bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP"), the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date (the "2seventy VWAP") multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP").

Footnote F3

The number of shares underlying the converted 2seventy equity awards was determined by multiplying the number of shares underlying the existing bluebird equity awards by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the sum of (1) the 2seventy VWAP multiplied by the distribution ratio and (2) the quotient obtained by dividing the bluebird Post-Distribution VWAP by the distribution ratio. bluebird equity awards granted on or after January 1, 2021, such equity awards were converted into 2seventy equity awards. The number of shares of 2seventy common stock underlying such converted equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the 2seventy VWAP.

Footnote F4

Includes 2,650 shares of 2seventy's common stock received in a pro rata distribution by bluebird as a result of the Separation.

Footnote F5

Represents options to purchase shares of 2seventy's common stock granted to the reporting person in connection with the Separation (see footnotes 2 and 3).

Footnote F6

This option is fully vested and exercisable as of the date hereof (see footnotes 2 and 3).

Footnote F7

This option vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders (see footnotes 2 and 3).

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .